VOQUZ Labs AG Foresees Strong Growth and Continues M&A Strategy

NuWays AG has released an analysis on VOQUZ Labs AG, maintaining a "Buy" recommendation with a target price of EUR 22.00. The research highlighted VOQUZ Labs AG's strong momentum, driven by increased demand for its flagship solution samQ and support from recent partnerships, notably with PwC. The company's growth strategy is reinforced by the successful launch of visoryQ, an SAP-ERP business case builder, which is expected to see dynamic sales growth in response to the accelerating S/4HANA transformation.

Further, VOQUZ Labs AG is set to continue its buy and build strategy after acquiring remedyne in 2023. The company plans to pursue acquisitions in the SAP add-on space to foster cross-selling opportunities and enhance its product offerings. Though smaller acquisitions could be funded internally, larger investments may require tapping into the capital market, according to CEO Martin Kögel.

Trading at attractive valuations and with strong growth prospects ahead, VOQUZ Labs AG is deemed undervalued by analysts. The company's high scalability and efficient business model underscore its appeal to investors, supporting the reiterated BUY rating.